![join-team-bg](https://stanfordima.wpenginepowered.com/wp-content/uploads/join-team-bg.png)
Alliances
Help Us Shape the Future of Medicines
To realize our mission of translating a great scientific idea into a real, transformative medicine for patients, we rely on external partners who bring expertise, investment, and scaling capacity to our pipeline. It’s these critical partnerships that ensure there is a path to patients beyond the walls of Stanford.
“The IMA continues to seek high-quality partners in our mission as an accelerator, and we are excited about engaging diverse partners in helping us scale Stanford-grown solutions.”
Chaitan Khosla
Director
Featured Alliances
Learn more about some of the alliances that are critical to our success.
![](https://ima.stanford.edu/wp-content/uploads/omniab-e1710871156611-400x284.png)
OmniAb
OmniAb® provides partners access to the most diverse antibody repertoires and cutting-edge screening technologies to enable discovery of next-generation therapeutics.
![](https://ima.stanford.edu/wp-content/uploads/orange_backgroun_cycle_shape-15-400x284.png)
Celltaxis
Celltaxis and the IMA are collaborating to test a new medicine for lymphedema.
![Decorative image](https://ima.stanford.edu/wp-content/uploads/vergent-400x284.jpeg)
Vergent Bioscience
This collaboration enables the clinical testing of imaging agents to improve surgical outcomes.
![](https://ima.stanford.edu/wp-content/uploads/alliance-the-invus-group-featimg-400x284.jpg)
The Invus Group
The investment firm is supporting the development of treatments for glioblastoma.
![](https://ima.stanford.edu/wp-content/uploads/alliance-intonation-research-featimg-400x284.jpg)
Intonation Research Laboratories
This collaboration with Intonation, a contract research organization, aims to develop treatments for neuroendocrine tumors.
![](https://ima.stanford.edu/wp-content/uploads/alloy-therapeutics-thumb-400x284.jpg)
Alloy Therapeutics
Alloy’s immunocompetent transgenic mice enable best-in-class in vivo human antibody discovery.
![](https://ima.stanford.edu/wp-content/uploads/0001_Layer-asdfgasf3-1-400x284.jpg)
Simcere Pharmaceutical
This collaboration with Simcere Pharmaceutical enables the lead identification of a novel therapeutic for Parkinson’s disease.
![](https://ima.stanford.edu/wp-content/uploads/twist-bioscience-featimg-400x284.jpg)
Twist Bioscience
Twist’s “Library of Libraries” and other services accelerate the discovery of antibody and other biologics-focused therapies.
![](https://ima.stanford.edu/wp-content/uploads/Photo_Acceleration_0002_Layer-4-1-400x284.jpg)
Porter Alliance for Innovative Medicines
This collaboration with Deerfield Management Company supports projects with the potential to cure life-altering diseases.
Come on Board
Our partners are critical to our success.
![](https://stanfordima.wpenginepowered.com/wp-content/uploads/Paul-Humphries-1.jpg)
Looking to start an alliance with us? Have questions?
Contact Alliance Director Paul Humphries.
Related Articles
![](https://ima.stanford.edu/wp-content/uploads/feat-img-wrg-400x284.jpg)
Stanford University and The Invus Group collaborate to develop glioblastoma drugs
![](https://ima.stanford.edu/wp-content/uploads/0001_Layer-3-rtshrth1-400x284.jpg)
Stanford University’s Innovative Medicines Accelerator and Intonation Research Laboratories form a collaboration to fight cancerous neuroendocrine tumors
![](https://ima.stanford.edu/wp-content/uploads/online-marketing-hIgeoQjS_iE-unsplash-400x284.jpg)